{"id":"placebo-to-match-albiglutide","safety":{"commonSideEffects":[{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL2107841","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not have a direct mechanism of action. However, it is designed to mimic the effects of albiglutide, which works by binding to and activating the GLP-1 receptor, thereby increasing insulin secretion and decreasing glucagon levels.","oneSentence":"This drug is a placebo that matches the mechanism of albiglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:39.880Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02802514","phase":"PHASE4","title":"A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-09-20","conditions":"Diabetes Mellitus","enrollment":5},{"nctId":"NCT02284009","phase":"PHASE2","title":"Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-10","conditions":"Diabetes Mellitus, Type 1","enrollment":67},{"nctId":"NCT02683746","phase":"PHASE3","title":"Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-16","conditions":"Diabetes Mellitus, Type 2","enrollment":308},{"nctId":"NCT02465515","phase":"PHASE4","title":"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-01","conditions":"Diabetes Mellitus","enrollment":9463},{"nctId":"NCT03015519","phase":"PHASE3","title":"A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2017-08-14","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT01406262","phase":"PHASE1","title":"Albiglutide Thorough ECG Study in Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-06","conditions":"Diabetes Mellitus, Type 2","enrollment":94},{"nctId":"NCT01098539","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":507},{"nctId":"NCT01098461","phase":"PHASE2","title":"Dose Ranging Study of Albiglutide in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Diabetes Mellitus, Type 2","enrollment":215},{"nctId":"NCT00838903","phase":"PHASE3","title":"Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1049},{"nctId":"NCT00849017","phase":"PHASE3","title":"Safety and Efficacy Study of Albiglutide in Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01","conditions":"Diabetes Mellitus, Type 2","enrollment":309},{"nctId":"NCT00839527","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":685},{"nctId":"NCT02660736","phase":"PHASE1","title":"Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-02","conditions":"Diabetes Mellitus, Type 2","enrollment":59},{"nctId":"NCT01733758","phase":"PHASE3","title":"A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02","conditions":"Diabetes Mellitus, Type 2","enrollment":494},{"nctId":"NCT02229240","phase":"PHASE3","title":"Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-08","conditions":"Diabetes Mellitus, Type 2","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo to match albiglutide","genericName":"placebo to match albiglutide","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug is a placebo that matches the mechanism of albiglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}